After patients enrol in clinical trials, regular assessments and testing – often requiring clinic visits – can become onerous and reduce the chances they will stick with t
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regul
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
